Thermo Fisher Reports Strong Q3 Growth Amid New Product Launches and Approvals

Thermo Fisher Scientific, a leading biopharma service provider and supplier, has reported a 5% year-over-year increase in sales for the third quarter of 2025, generating $11.12 billion in revenue. The company's growth strategy appears to be paying dividends, with recent product launches and regulatory approvals contributing to its positive financial performance.

Companion Diagnostic Approval Boosts Portfolio

A significant contributor to Thermo Fisher's success this quarter was the FDA approval of its Oncomine Dx Express Test as a companion diagnostic for Dizal Pharma's Zegfrovy. This drug, approved for treating adults with locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations, represents a major advancement in targeted cancer therapy. The companion diagnostic test will play a crucial role in identifying eligible patients for this treatment.

Expansion into Neurodegenerative Disease Research

Further solidifying its position in the diagnostics market, Thermo Fisher recently launched a research test designed to profile dozens of proteins linked to neurodegenerative diseases. This multiplex protein panel aims to aid in the development of new clinical biomarkers for conditions such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and multiple sclerosis. This move demonstrates the company's commitment to advancing scientific research in critical areas of unmet medical need.

Strategic Initiatives and Future Outlook

Marc Casper, chairman, president and CEO of Thermo Fisher, expressed satisfaction with the company's strategic execution, highlighting new product launches, complementary acquisitions, and a collaboration with OpenAI to accelerate scientific advancement. Despite recent layoffs at its California facilities, likely a response to the post-pandemic market normalization, Casper remains optimistic about the company's future. He stated, "Looking ahead, we're in a great position to deliver on our 2025 objectives as we continue to drive long-term value creation for all stakeholders and build an even brighter future for our company."